Clearwater Analytics Holdings, INC Form 4 insider transactions
NYSE
Form 4: Clearwater Analytics CEO Sandeep Sahai Executes Stock Options and Sells Shares Under 10b5-1 Plan
Clearwater Analytics CEO Sandeep Sahai exercised stock options, sold shares to cover tax obligations, and executed sales under a pre-arranged 10b5-1 trading plan.
NYSE
Clearwater Analytics CFO James Cox exercised stock options and sold shares to cover tax obligations, according to a recent SEC Form 4 filing.
NYSE
425: Clearwater Analytics and Enfusion Announce Preliminary Results of Merger Consideration Election
Clearwater Analytics and Enfusion have announced the preliminary results of the election by Enfusion shareholders regarding the form of merger consideration they wish to receive in connection with Clearwater's acquisition of Enfusion.
NYSE
Clearwater Analytics CEO Sandeep Sahai exercised stock options and sold shares to cover tax obligations, while also selling shares under a pre-arranged trading plan.
NYSE
Clearwater Analytics and Enfusion have set April 16, 2025, as the deadline for Enfusion shareholders to elect the form of merger consideration they wish to receive in connection with Clearwater's acquisition of Enfusion.
NYSE
Clearwater Analytics CFO James S. Cox reports the vesting and subsequent sale of shares to cover tax obligations related to restricted stock units.
NYSE
Clearwater Analytics CEO Sandeep Sahai reports acquisition and disposal of Class A Common Stock and Restricted Stock Units related to vesting and tax obligations.
NYSE
Chief Technology Officer Das Souvik reports the acquisition and disposal of Class A Common Stock and Restricted Stock Units in Clearwater Analytics Holdings, Inc. due to vesting and tax obligations.
NYSE
Clearwater Analytics Holdings Inc.'s Chief Revenue Officer, Scott Stanley Erickson, disposed of shares to cover tax withholding obligations related to the vesting of Restricted Stock Units.
NYSE
Subi Sethi, Chief Client Officer of Clearwater Analytics Holdings, reports the vesting and disposal of shares to cover tax obligations.
NYSE
Clearwater Analytics and Enfusion announce a supplement to their merger proxy statement, modifying the joint election procedure for Enfusion stockholders.
NYSE
Director Kathleen Corbet sold 7,527 shares of Clearwater Analytics Holdings, Inc. on March 17, 2025, at a price of $26.4733 per share.
NYSE
Clearwater Analytics CFO James S. Cox exercised stock options, disposed of shares to cover tax obligations, and sold shares under a pre-arranged 10b5-1 trading plan.
NYSE
Clearwater Analytics CEO Sandeep Sahai exercised stock options and sold shares on March 13, 2025, to cover tax obligations, while also selling shares under a pre-arranged Rule 10b5-1 trading plan.
NYSE
Form 4: Clearwater Analytics Executive Scott Erickson Executes Stock Option, Sells Shares to Cover Taxes
Clearwater Analytics' Chief Revenue Officer, Scott Erickson, exercised stock options and sold shares to cover tax obligations, as detailed in a recent SEC Form 4 filing.
NYSE
Chief Revenue Officer Scott Erickson reports exercising stock options and selling shares of Clearwater Analytics Holdings Inc. Class A Common Stock on March 3, 2025.
NYSE
Form 4: Clearwater Analytics Executive Scott Erickson Reports Stock Transactions Following PSU Vesting
Clearwater Analytics' Chief Revenue Officer, Scott Erickson, reports acquisition and disposal of Class A Common Stock following the vesting of performance stock units (PSUs) and subsequent sales to cover tax obligations.
NYSE
Clearwater Analytics CEO Sandeep Sahai reports acquisition and disposal of Class A Common Stock related to the vesting of performance stock units (PSUs) and subsequent sales to cover tax obligations.
NYSE
Subi Sethi, Chief Client Officer of Clearwater Analytics, reports acquisition and disposal of Class A Common Stock related to the vesting of performance stock units (PSUs) and subsequent sales to cover tax obligations.
NYSE
Souvik Das, Chief Technology Officer of Clearwater Analytics, reports the acquisition and disposal of Class A Common Stock related to the vesting of performance stock units (PSUs) and subsequent sales to cover tax obligations.
NYSE
Clearwater Analytics CFO James S. Cox reports acquisition and disposal of Class A Common Stock related to the vesting of performance stock units (PSUs) and subsequent sales to cover tax obligations.
NYSE
Form 4: Clearwater Analytics Holdings, Inc.: Chief Technology Officer Acquires 82,500 Restricted Stock Units
Souvik Das, Chief Technology Officer of Clearwater Analytics Holdings, Inc., reports the acquisition of 82,500 Restricted Stock Units (RSUs) on February 13, 2025, vesting quarterly over the next four years.
NYSE
Clearwater Analytics Holdings CEO Sandeep Sahai reports the acquisition of 351,852 Restricted Stock Units (RSUs) on February 13, 2025, according to a Form 4 filing with the SEC.
NYSE
Form 4: Clearwater Analytics Holdings Officer Subi Sethi Reports Acquisition of Restricted Stock Units
Subi Sethi, Chief Client Officer of Clearwater Analytics Holdings, reports the acquisition of 125,000 Restricted Stock Units (RSUs) on February 13, 2025, according to a Form 4 filing with the SEC.
NYSE
Scott Stanley Erickson, Chief Revenue Officer of Clearwater Analytics Holdings, Inc., acquired 82,500 restricted stock units on February 13, 2025, according to a Form 4 filing.
NYSE
Clearwater Analytics CFO James Cox reports the exercise of stock options, tax withholding, and sales of Class A Common Stock.
NYSE
Clearwater Analytics CEO Sandeep Sahai exercised stock options and sold shares to cover tax obligations, as reported in a recent SEC Form 4 filing.
NYSE
Clearwater Analytics' Chief Financial Officer, James S. Cox, exercised stock options and sold shares to cover tax obligations and under a pre-arranged trading plan.
NYSE
Form 4: Clearwater Analytics CEO Sandeep Sahai Executes Stock Option, Sells Shares Under 10b5-1 Plan
Clearwater Analytics CEO Sandeep Sahai exercised stock options and sold 50,000 shares of Class A Common Stock on January 13, 2025, under a pre-arranged Rule 10b5-1 trading plan.
NYSE
Clearwater Analytics plans to acquire Enfusion for approximately $760 million in cash and stock, aiming to create a comprehensive front-to-back platform for the investment management industry.